The company said total revenues for Q2 2024 (ended June 30, 2024, 3 months) rose to $91,234 million, up 2.6% from $88,921 million a year earlier. GAAP diluted EPS was $1.41 and Adjusted EPS was $1.83.

1. 01

   The company said total revenues for Q2 2024 (ended June 30, 2024, 3 months) rose to $91,234 million, up 2.6% from $88,921 million a year earlier. GAAP diluted EPS was $1.41 and Adjusted EPS was $1.83.

2. 02

   The company said the Health Care Benefits segment's medical benefit ratio for Q2 rose to 89.6% from 86.2% a year earlier, and adjusted operating income fell $603 million to $938 million. It cited higher utilization and the unfavorable impact of Medicare Advantage star ratings as factors.

3. 03

   The company said it revised its full-year 2024 Adjusted EPS guidance to a range of $6.40 to $6.65 from at least $7.00, and its GAAP diluted EPS guidance to a range of $4.95 to $5.20 from at least $5.64. It also revised its cash flow from operations guidance to approximately $9.0 billion from at least $10.5 billion.

4. 04

   The company said net cash provided by operating activities was $7,992 million for the 6 months ended June 30, 2024. It said it made leadership changes in the Health Care Benefits segment effective immediately: Brian Kane is leaving the company, and Karen Lynch will assume direct leadership of the segment.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.